Abstract:Background Chemokine‐like factor 1 (CKLF1) may be involved in the inflammatory response and secondary brain injury after severe traumatic brain injury (sTBI). We determined serum CKLF1 levels of sTBI patients to further investigate the correlation of CKLF1 levels with disease severity, functional prognosis, and 180‐day mortality of sTBI. Methods Serum CKLF1 levels were measured at admission in 119 sTBI patients and at entry into study in 119 healthy controls. Serum CKLF levels of 50 patients were also quantified at days 1–3, 5, and 7 after admission. Glasgow coma scale (GCS) scores and Rotterdam computerized tomography (CT) classification were utilized to assess disease severity. Extended Glasgow outcome scale (GOSE) scores were recorded to evaluate function prognosis at 180 days after sTBI. Relations of serum CKLF1 levels to 180‐day poor prognosis (GOSE scores of 1–4) and 180‐day mortality were analyzed using univariate analysis, followed by multivariate analysis. Receiver‐operating characteristic (ROC) curve was built to investigate prognostic predictive capability. Results Serum CKLF1 levels of sTBI patients increased at admission, peaked at day 2, and then gradually decreased; they were significantly higher during the 7 days after sTBI than in healthy controls. Differences of areas under ROC curve (areas under the curve [AUCs]) were not significant among the six time points. Multivariate analysis showed that serum CKLF1 levels were independently correlated with GCS scores, Rotterdam CT classification, and GOSE scores. Serum CKLF1 levels were significantly higher in non‐survivors than in survivors and in poor prognosis patients than in good prognosis patients. Serum CKLF1 levels independently predicted 180‐day poor prognosis and 180‐day mortality, and had high 180‐day prognosis and mortality predictive abilities, and their AUCs were similar to those of GCS scores and Rotterdam CT classification. Combination model containing serum CKLF1, GCS scores, and Rotterdam CT classification performed more efficiently than any of them alone in predicting mortality and poor prognosis. The models were visually described using nomograms, which were comparatively stable under calibration curve and were relatively of clinical benefit under decision curve. Conclusion Serum CKLF1 levels are significantly associated with disease severity, poor 180‐day prognosis, and 180‐day mortality in sTBI patients. Hence, complement CKLF1 may serve as a potential prognostic biomarker of sTBI.

Serum netrin-1 as a potential biomarker for functional outcome of traumatic brain injury

Serum Albumin And Prealbumin Predict The Poor Outcome Of Traumatic Brain Injury

The Prognostic Value of Deleted in Colorectal Cancer (DCC) Receptor and Serum Netrin-1 in Severe Traumatic Brain Injury

The Predictive Role of Systemic Inflammation Response Index in the Prognosis of Traumatic Brain Injury: A Propensity Score Matching Study.

Serum netrin-1 concentrations are associated with clinical outcome in acute intracerebral hemorrhage

Neuroglobin and Nogo-a as biomarkers for the severity and prognosis of traumatic brain injury.

Study on Serum Mir-185-5p in Assessing the Injury Severity and Prognosis of Patients with Traumatic Brain Injury.

Serum Biomarkers and Disease Progression in CT-negative Mild Traumatic Brain Injury.

Utility of serum chemokine–like factor 1 as a biomarker of severity and prognosis after severe traumatic brain injury: A prospective observational study

Lactic Acid, Neuron-Specific Enolase, and Blood-Brain Barrier Index after a Severe Traumatic Brain Injury: a Prospective Study

Relationship between cerebrospinal fluidα-Synuclein and prognosis of patients with traumatic brain injury

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury

Role of Diffusion Tensor Imaging Combined with Neuron-Specific Enolase and S100 Calcium-binding Protein B Detection in Predicting the Prognosis of Moderate and Severe Traumatic Brain Injury

Serum calprotectin as a prognostic predictor in severe traumatic brain injury

Association between Blood and Computed Tomographic Imaging Biomarkers in a Cohort of Mild Traumatic Brain Injury Patients

Serum exosomes miR-206 and miR-549a-3p as potential biomarkers of traumatic brain injury

Diagnostic and prognostic utility of plasma thrombospondin-1 levels in traumatic brain injury

Serum Neuron-Specific Enolase Levels Associated with Connectivity Alterations in Anterior Default Mode Network after Mild Traumatic Brain Injury

Multiplex Assessment of Serum Chemokines CCL2, CCL5, CXCL1, CXCL10, and CXCL13 Following Traumatic Brain Injury

Admission levels of serum biomarkers have additive and cumulative prognostic value in traumatic brain injury

A two-center prospective cohort study of serum RIP-3 as a potential biomarker in relation to severity and prognosis after severe traumatic brain injury